AtheroGenics, Inc.

FDA grants approval for protocol amendment to ARISE phase III trial

Published in Law and Health Weekly, April 2nd, 2005

AtheroGenics, Inc., (AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its proposed amendment to the ARISE phase III clinical trial protocol.

The ARISE phase III clinical trial is testing the company's lead compound, AGI-1067, for the oral treatment of atherosclerosis in leading cardiovascular research centers throughout the United States, Canada, the United Kingdom and South Africa.

The changes to the ARISE protocol are intended to enhance the trial as well as to accelerate its pace, without adversely affecting its Special Protocol...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-04-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry